Company profile
Soligenix, Inc.
NASDAQ: SNGX · Healthcare · Biotechnology
#1033 of 1,418 Healthcare companies by revenuebottom-quartile growth
EA Score
42DFH 21DQ 78GM 29SS 56
v0.1 · 65/100 weight · provisional
↑ listing tenure, disclosure history · ↓ Piotroski F, operating margin
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$11.1M
Employees
14
as of 2026-08-24
Market cap
$5.9M
as of 2026-08-24
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$119.4k$119.4k2024
Net income-$11.1M-$11.1M2025
Operating income-$11.8M-$11.8M2025
Total assets$9.2M$9.2M2025
Liabilities$3.9M$3.9M2025
Equity$5.3M$5.3M2025
Revenue trend
FY2018 – FY2024 · USD
FY18
FY18
FY19
FY20
FY21
FY22
FY23
FY24
Revenue by segment
Filed disclosures · FY2024
By product
Grant revenue100%
By geography
Not disclosed.
The read
What is Soligenix, Inc.’s revenue?
Soligenix, Inc. booked $119.4k in FY2024 revenue, contracting 86% year over year — slower than 89% of Healthcare companies we track, at a -9282.3% net margin.
Peers · Healthcare
Advanced BioMedical Technologies Inc.——AI/ML Innovations Inc.——Viracta Therapeutics, Inc.——Microbot Medical Inc.54DBullfrog AI Holdings, Inc. Common Stock30DCreative Edge Nutrition, Inc.——Neighbors
Mercer →Key facts
CEOChristopher J. Schaber
SectorHealthcare
IndustryBiotechnology
HeadquartersPrinceton, NJ
ExchangeNASDAQ: SNGX
Employees14
IPO date1994-04-04
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.